30-Second Scoop:
A new antiretroviral pill, MK-8527, could offer monthly protection against HIV. Early trials show it is safe and maintains protective drug levels for over 28 days. Large-scale phase-three trials are set to begin soon, comparing its effectiveness to daily PrEP pills. If successful, this could revolutionize HIV prevention by providing a convenient, long-acting oral option.
Spotlight on MK-8527: A Potential Game-Changer in HIV Prevention
The fight against HIV has seen remarkable progress with various prevention tools, including daily oral PrEP, long-acting injectables, and vaginal rings. Now, a new contender MK-8527, a once-monthly oral pill—has shown promising early results and is advancing to large-scale trials.
How Does It Work?
MK-8527 is a nucleoside reverse transcriptase translocation inhibitor, disrupting a key step in HIV’s replication process. Unlike daily PrEP, this pill is designed to provide protection for up to a month per dose, making adherence easier for some users.
Phase-Two Trial Results
Presented at the International AIDS Society (IAS) conference in Kigali, Rwanda, the phase-two study tested three doses (3mg, 6mg, and 12mg) in 350 low-risk participants across South Africa, the U.S., and Israel. Key findings:
- Well-tolerated, with safety similar to a placebo.
- 6mg and 12mg doses maintained protective drug levels for over 28 days.
- No HIV infections occurred during the trial.
- Side effects (headache, nausea, fatigue) were mild and comparable to placebo.
Notably, the drug may work within an hour of ingestion, according to modeling data.
Safety Concerns & Next Steps
While generally safe, one spontaneous abortion in the 3mg group was flagged as a possible drug-related event. Additionally, two participants (one in the 6mg group, one in the 12mg group) dropped out due to side effects.
The next phase two large phase-three trials (EXPrESSIVE-10 and EXPrESSIVE-11) will compare MK-8527’s effectiveness against daily PrEP in multiple countries, including South Africa. Results are expected in at least two years.
Why a Monthly Pill Matters
With existing options like six-month injectable lenacapavir (recently approved in the U.S.), why pursue a monthly pill? Experts say choice is key:
- “Some people don’t like injections. A pill is simple,” says Prof. Linda-Gail Bekker (Desmond Tutu Health Foundation).
- “Twelve pills a year is a remarkable advance,” adds Mitchell Warren (AVAC).
The Road Ahead
If successful, MK-8527 could offer a convenient, discreet, and accessible HIV prevention method especially in regions where daily adherence is challenging. With global HIV funding under strain, an affordable, long-acting pill could be a crucial addition to the prevention toolkit.
For now, the world watches as phase-three trials begin hoping this pill could be the next breakthrough in ending HIV.
Discover more from 30 seconds
Subscribe to get the latest posts sent to your email.
